TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Nonfarm Payrolls (September)
SLN

Silence Therapeutics PLC

Healthcare · Biotechnology

10.90$ +1.2% vs. previous close Closing price · As of: Sep 30, 2026

Ownership

Ownership Structure

Who owns Silence Therapeutics PLC (SLN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 60.9% of the shares are freely tradable; institutional investors hold 44.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 44.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 21.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 60.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 62Mio.

Largest Shareholders

Institutions

Institutions SLN
Name Stake (%) Shares Change (%) Date
TCG Crossover Management, LLC 4.88 3,033,560 +0.0 06/30/2026
Siren, L.L.C. 4.68 2,911,438 +0.0 03/31/2026
Redmile Group, LLC 3.48 2,164,777 +0.0 06/30/2026
Nantahala Capital Management, LLC 3.45 2,146,731 +39.2 03/31/2026
Citadel Advisors Llc 2.14 1,329,625 +7.7 06/30/2026
Nextech Invest, Ltd. 1.53 952,400 +0.0 06/30/2026
Millennium Management LLC 1.46 909,279 -15.4 06/30/2026
Ikarian Capital, LLC 1.39 865,784 +0.0 03/31/2026
Polygon Management Ltd 1.23 764,256 +21.3 06/30/2026

Funds

Funds SLN
Name Stake (%) Shares Change (%) Date
International Biotechnology Ord 1.17 729,620 +0.0 05/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?